Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.


Journal

Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213

Informations de publication

Date de publication:
05 2021
Historique:
received: 18 12 2019
accepted: 03 11 2020
pubmed: 4 1 2021
medline: 29 5 2021
entrez: 3 1 2021
Statut: ppublish

Résumé

The aim of our study was to assess concordance of staging laparoscopy and cytoreductive surgery (CRS) peritoneal cancer index (PCI) when applying a two-step surgical protocol. We also aimed to evaluate the accuracy of diagnostic laparoscopy to triage patients for complete cytoreduction, and to define optimal time between staging laparoscopy and CRS. We designed a retrospective review of prospectively collected data from patients with advanced ovarian cancer who underwent a diagnostic laparoscopy followed by a CRS a few weeks later (two-step surgical protocol), from January 2010 to April 2019. Only patients selected for complete cytoreduction, and with available PCI score from both surgeries were included. PCI concordance was assessed using intraclass correlation coefficient (ICC). During the study period 543 patients underwent a laparoscopic staging for ovarian carcinomatosis. Among them, 43 patients fulfilled inclusion criteria. ICC between laparoscopic and laparotomic PCI was 0.54. After applying the linear regression equation: laparoscopic PCI + 0.2 x [days between surgeries] + 2, ICC increased to 0.79. Completeness cytoreduction score and laparoscopic PCI were significantly associated (OR 1.27, 95% CI 1.03-1.57, p = 0.03). AUC of laparoscopic PCI to predict complete cytoreduction was 0.90. Concordance between laparoscopic PCI assessment and PCI score at the end of CRS is fair within a two-step surgical management. Laparoscopic assessment underestimates final PCI score by two points, and this difference increases with the delay between both surgeries. Diagnostic laparoscopy can adequately select patients for CRS, and optimal time to perform it is no more than 10 days after laparoscopy.

Identifiants

pubmed: 33389113
doi: 10.1007/s00404-020-05874-y
pii: 10.1007/s00404-020-05874-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1295-1304

Références

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564. https://doi.org/10.1016/j.ygyno.2006.03.051
doi: 10.1016/j.ygyno.2006.03.051 pubmed: 16714056
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248
doi: 10.1200/JCO.2002.20.5.1248 pubmed: 11870167
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Mackey D (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194–3200. https://doi.org/10.1200/JCO.2003.02.153
doi: 10.1200/JCO.2003.02.153 pubmed: 12860964
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline. Gynecol Oncol 143:3–15. https://doi.org/10.1016/j.ygyno.2016.05.022
doi: 10.1016/j.ygyno.2016.05.022 pubmed: 27650684 pmcid: 5413203
NCCN, Ovarian Cancer, Humana Press, Totowa, NJ, 2013. https://doi.org/10.1007/978-1-62703-547-7
Brun J-L, Rouzier R, Selle F, Houry S, Uzan S, Daraï E (2009) Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer 9:171. https://doi.org/10.1186/1471-2407-9-171
doi: 10.1186/1471-2407-9-171 pubmed: 19500391 pmcid: 2701965
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT (2015) Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137:553–558. https://doi.org/10.1016/j.ygyno.2015.03.049
doi: 10.1016/j.ygyno.2015.03.049 pubmed: 25827290 pmcid: 4825172
Rutten MJ, Van Meurs HS, Van De Vrie R, Naaktgeboren CA, Fons G, Opmeer BC, Spijkerboer A, Bossuyt PMM, Kenter GG, Buist MR, Gaarenstroom KN, Van Gorp T, Brugge HGT, Hofhuis W, Schreuder HWR, Van Haaften M, Arts HJG, Zusterzeel PLM, Pijnenborg JMA, Vos MC, Engelen MJA, Boss EA, Gerestein KG, Schutter EMJ, Mol BW (2017) Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol 35:613–621. https://doi.org/10.1200/JCO.2016.69.2962
doi: 10.1200/JCO.2016.69.2962 pubmed: 28029317
Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:254–261
doi: 10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U
Tentes A-AK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K (2003) Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 29:69–73
doi: 10.1053/ejso.2002.1380
Gouy S, Belghiti J, Uzan C, Canlorbe G, Gauthier T, Morice P (2013) Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer 23:1699–1703. https://doi.org/10.1097/IGC.0b013e3182a616a7
doi: 10.1097/IGC.0b013e3182a616a7 pubmed: 24100589
Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, Glehen O (2006) Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 32:597–601. https://doi.org/10.1016/j.ejso.2006.03.002
doi: 10.1016/j.ejso.2006.03.002 pubmed: 16617003
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42. https://doi.org/10.1097/00000658-199501000-00004
doi: 10.1097/00000658-199501000-00004 pubmed: 7826158 pmcid: 1234492
Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA (2007) A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 107:99–106. https://doi.org/10.1016/j.ygyno.2007.05.032
doi: 10.1016/j.ygyno.2007.05.032 pubmed: 17602726
Martinez A, Ngo C, Leblanc E, Gouy S, Luyckx M, Darai E, Classe JM, Guyon F, Pomel C, Ferron G, Filleron T, Querleu D (2016) Surgical complexity impact on survival after complete cytoreductive surgery for advanced ovarian cancer. Ann Surg Oncol 23:2515–2521. https://doi.org/10.1245/s10434-015-5069-z
doi: 10.1245/s10434-015-5069-z pubmed: 27008588
Cicchetti DV (1994) Interreliability Standards in Psychological Evaluations. Psychol Assess: 284–290
Bailly C, Bailly-Glatre A, Alfidja A, Vincent C, Dauplat J, Pomel C (2009) Peritoneal carcinosis in ovarian cancer: conventional imaging (CT-scan and MRI). Bull Cancer 96:1155–1162
doi: 10.1684/bdc.2009.0981
Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH (2007) Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25:384–389. https://doi.org/10.1200/JCO.2006.07.7800
doi: 10.1200/JCO.2006.07.7800 pubmed: 17264334 pmcid: 17264334
De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, Cacciari N, Al-Nahhas A, Rubello D, Venturoli S, Fanti S (2011) FDG-PET/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 80:e98–e103. https://doi.org/10.1016/j.ejrad.2010.07.013
doi: 10.1016/j.ejrad.2010.07.013 pubmed: 20688446
Lee M, Kim WS, Paek J, Lee HS, Yim WG, Kim HJ, Kim WJ, Kim TY, Nam JE (2011) Comparisons of surgical outcomes, complications, and costs between laparotomy and laparoscopy in early-stage ovarian cancer. Int J Gynecol Cancer 21:251–256. https://doi.org/10.1097/IGC.0b013e318208c71c
doi: 10.1097/IGC.0b013e318208c71c pubmed: 21270608
Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, Scambia G (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma : a pilot study. Ann Surg Oncol 13:1156–1161. https://doi.org/10.1245/ASO.2006.08.021
doi: 10.1245/ASO.2006.08.021 pubmed: 16791447 pmcid: 16791447
Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND (2018) Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol 151:428–432. https://doi.org/10.1016/j.ygyno.2018.10.017
doi: 10.1016/j.ygyno.2018.10.017 pubmed: 30366647 pmcid: 6281799
Nick AM, Coleman RL, Ramirez PT, Sood AK (2015) A Framework for personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol 12:239–245. https://doi.org/10.1038/nrclinonc.2015.26
doi: 10.1038/nrclinonc.2015.26 pubmed: 25707631 pmcid: 4528308
Bristow RE, Duska LR, Lambrou NC, Fishman EK, Neill MJO, Trimble EL, Montz FJ (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography:1532–1540.
Elias D, Souadka A, Fayard F, Mauguen A, Dumont F, Honore C, Goere D (2012) Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol 38:503–508. https://doi.org/10.1016/j.ejso.2012.01.001
doi: 10.1016/j.ejso.2012.01.001 pubmed: 22281154
Rutten MJ, Leeflang MM, Kenter GG, Mol BWJ, Buist M (2014) Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009786.pub2
doi: 10.1002/14651858.CD009786.pub2 pubmed: 24563459 pmcid: 6457797
Llueca A, Serra A, Rivadulla I, Gomez L, Escrig J, Játiva-Porcar R, Moreno-Clarí E, Montañés-Pauls B, Bellver M, Maiocchi K, Medina-Medina C, Delgado-Barriga K, Rodrigo-Aliaga M, Ruiz N, Herrero C, Maazouzi Y, Piquer D, Segarra B, Del Moral R (2018) Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. Surg Oncol World J. https://doi.org/10.1186/s12957-018-1339-0
doi: 10.1186/s12957-018-1339-0
Dessapt AL, Huchon C, Ngo C, Bats AS, Bensaid C, Lecuru F (2016) Is complete cytoreductive surgery feasible in this patient with ovarian cancer? Surg Oncol 25:326–331. https://doi.org/10.1016/j.suronc.2016.07.001
doi: 10.1016/j.suronc.2016.07.001 pubmed: 27566040
Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M, Genta S, Lucchino F, Marocco F, Borella F, Valabrega G, Ponzone R (2018) A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. J Ovarian Res. https://doi.org/10.1186/s13048-018-0415-y
doi: 10.1186/s13048-018-0415-y pubmed: 29843747 pmcid: 5975698
Rosendahl M, Harter P, Bjørn SF, Høgdall C (2018) Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28:316–322. https://doi.org/10.1097/IGC.0000000000001173
doi: 10.1097/IGC.0000000000001173 pubmed: 29324538
Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, Salerno MG, Scambia G (2008) Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 199:642.e1-642.e6. https://doi.org/10.1016/j.ajog.2008.06.052
doi: 10.1016/j.ajog.2008.06.052
Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, Petruzzelli F, Ghezzi F, Garzarelli S, Mereu L, Viganò R, Tateo S, Fanfani F, Scambia G (2013) A multicentric trial (Olympia–MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209:462.e1-462.e11. https://doi.org/10.1016/j.ajog.2013.07.016
doi: 10.1016/j.ajog.2013.07.016
Brun J-L, Rouzier R, Uzan S, Daraï E (2008) External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score. Gynecol Oncol 110:354–359. https://doi.org/10.1016/j.ygyno.2008.04.042
doi: 10.1016/j.ygyno.2008.04.042 pubmed: 18572226
Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202:178.e1-178.e10. https://doi.org/10.1016/j.ajog.2009.10.856
doi: 10.1016/j.ajog.2009.10.856

Auteurs

Martina Aida Angeles (MA)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Federico Migliorelli (F)

Department of Gynecology and Obstetrics, Centre Hospitalier Intercommunal Des Vallées de L'Ariège, St Jean de Verges, France.

Mathilde Del (M)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Carlos Martínez-Gómez (C)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
INSERM CRCT 1, Toulouse, France.

Manon Daix (M)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Sarah Bétrian (S)

Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Erwan Gabiache (E)

Department of Nuclear Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Gisèle Balagué (G)

Department of Radiology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Sophie Leclerc (S)

Department of Anesthesiology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Eliane Mery (E)

Department of Anatomopathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Laurence Gladieff (L)

Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France.

Gwénaël Ferron (G)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
INSERM CRCT 19, Toulouse, France.

Alejandra Martinez (A)

Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France. Martinez.Alejandra@iuct-oncopole.fr.
INSERM CRCT 1, Toulouse, France. Martinez.Alejandra@iuct-oncopole.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH